Effect of computerized coronary heart disease risk assessment on the use of lipid-lowering therapy in general practice patients

Coronary Health Care

Volumn 5, Issue 1, 2001, Pages 4-8

  Ford, D R ^a   Walker, J ^a   Game, F L ^a   Bartlett, W A ^a   Jones, A F ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL;

ADULT; ANAMNESIS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPUTER ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; DRUG WITHDRAWAL; FEMALE; GENERAL PRACTICE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MOTIVATION; PRACTICE GUIDELINE; PREDICTION; RISK ASSESSMENT; RISK MANAGEMENT; SECONDARY PREVENTION; SMOKING; UNITED KINGDOM;

EID: 0034747763     PISSN: 13623265     EISSN: None     Source Type: Journal    
DOI: 10.1054/chec.2000.0103     Document Type: Article

References (16)

1. Cardiovascular disease risk profiles
2. Management of hyperlipidaemia
3. Laboratory-based calculation of coronary heart disease risk in a hospital diabetes clinic
4. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
5. Indications for cholesterol-lowering medication: Comparison of risk assessment methods
6. A simple computer program for guiding management of cardiovascular risk factors and prescribing
7. Cardiovascular risk assessment
8. Clinical guidelines for the assessment and management of dyslipidaemia
9. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: An updated Sheffield table
10. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
11. Randomised controlled trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
12. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia
13. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
14. Joint british recommendations on prevention of coronary heart disease in clinical practice